Drug Profile
Research programme: PARP inhibitors - Rocket
Latest Information Update: 09 Jan 2018
Price :
$50
*
At a glance
- Originator Inotek Pharmaceuticals
- Class
- Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute lung injury; Age-related macular degeneration; Asthma; Chronic obstructive pulmonary disease; Diabetes mellitus; Diabetic retinopathy; Erectile dysfunction; Inflammatory bowel diseases; Multiple sclerosis; Rheumatoid arthritis; Stroke
Most Recent Events
- 04 Jan 2018 Rocket Pharmaceuticals merged with Inotek Pharmaceuticals and the combined company was named Rocket Pharmaceuticals
- 11 Jan 2011 Preclinical trials in Age-related macular degeneration in USA (unspecified route)
- 11 Jan 2011 Preclinical trials in Diabetic retinopathy in USA (unspecified route)